VSTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vestis Corp (VSTS) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company's financial performance is deteriorating, with significant YoY declines in revenue, net income, EPS, and gross margin. Technical indicators suggest a neutral to bearish trend, and options data reflects weak sentiment with low put-call ratios. Analyst ratings remain negative overall, with underweight and sell recommendations dominating. There are no significant positive catalysts or recent insider/congressional trades to suggest a turnaround. Given the investor's profile and preference for long-term growth, this stock does not align with their goals.
The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 54.324, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock is trading near key support levels, suggesting limited upside potential. The stock has a 50% chance to decline slightly in the short term (-1.39% next day, -1.02% next week, -0.26% next month).
NULL. There are no recent news events, insider trades, or congressional trades to act as positive catalysts.
The company's financial performance is significantly deteriorating, with revenue, net income, EPS, and gross margin all showing sharp YoY declines. Analyst ratings remain negative, with underweight and sell recommendations dominating. Hedge funds and insiders are neutral, indicating no confidence in the stock.
In Q1 2026, revenue dropped by -2.98% YoY to $663.39M. Net income plunged by -868.15% YoY to -$6.39M. EPS fell by -600% YoY to -$0.05. Gross margin decreased by -6.95% YoY to 20.63%. These metrics indicate significant financial deterioration.
Analyst sentiment is negative overall. Barclays, JPMorgan, and Goldman Sachs maintain underweight or sell ratings, despite minor price target increases. Baird is neutral but notes only a 'good start to the year,' which is insufficient to offset broader concerns.
